2021 Q2 Form 10-Q Financial Statement
#000119312521227389 Filed on July 28, 2021
Income Statement
| Concept | 2021 Q2 | 2020 Q4 |
|---|---|---|
| Revenue | $3.910B | $4.453B |
| YoY Change | 1.03% | 11.58% |
| Cost Of Revenue | $2.037B | $2.372B |
| YoY Change | -2.58% | 16.67% |
| Gross Profit | $1.873B | $2.081B |
| YoY Change | 5.28% | 6.28% |
| Gross Profit Margin | 47.9% | 46.73% |
| Selling, General & Admin | $857.0M | $965.0M |
| YoY Change | 4.13% | -2.62% |
| % of Gross Profit | 45.76% | 46.37% |
| Research & Development | $248.0M | |
| YoY Change | 2.48% | |
| % of Gross Profit | 13.24% | |
| Depreciation & Amortization | $305.0M | $395.0M |
| YoY Change | -20.16% | -5.05% |
| % of Gross Profit | 16.28% | 18.98% |
| Operating Expenses | $1.105B | $1.299B |
| YoY Change | 1.38% | 4.0% |
| Operating Profit | $582.0M | $782.0M |
| YoY Change | -15.53% | 10.3% |
| Interest Expense | -$254.0M | -$171.0M |
| YoY Change | 8.09% | -18.57% |
| % of Operating Profit | -43.64% | -21.87% |
| Other Income/Expense, Net | -$274.0M | -$97.00M |
| YoY Change | -2590.91% | -521.74% |
| Pretax Income | $308.0M | $137.0M |
| YoY Change | -703.92% | -451.28% |
| Income Tax | $98.00M | -$21.00M |
| % Of Pretax Income | 31.82% | -15.33% |
| Net Earnings | $207.0M | $149.0M |
| YoY Change | 47.86% | 35.45% |
| Net Earnings / Revenue | 5.29% | 3.35% |
| Basic Earnings Per Share | $0.19 | |
| Diluted Earnings Per Share | $0.19 | $136.1K |
| COMMON SHARES | ||
| Basic Shares Outstanding | 1.103B | |
| Diluted Shares Outstanding | 1.109B |
Balance Sheet
| Concept | 2021 Q2 | 2020 Q4 |
|---|---|---|
| SHORT-TERM ASSETS | ||
| Cash & Short-Term Investments | $2.436B | $2.177B |
| YoY Change | 1.42% | 10.23% |
| Cash & Equivalents | $2.436B | $2.177B |
| Short-Term Investments | ||
| Other Short-Term Assets | $1.536B | $1.844B |
| YoY Change | 4.28% | 32.57% |
| Inventory | $4.362B | $4.403B |
| Prepaid Expenses | ||
| Receivables | $4.488B | $4.581B |
| Other Receivables | $0.00 | $0.00 |
| Total Short-Term Assets | $12.82B | $13.01B |
| YoY Change | 0.32% | -3.41% |
| LONG-TERM ASSETS | ||
| Property, Plant & Equipment | $6.658B | $6.855B |
| YoY Change | 0.71% | -1.37% |
| Goodwill | $20.42B | $20.62B |
| YoY Change | -17.04% | -16.99% |
| Intangibles | ||
| YoY Change | ||
| Long-Term Investments | ||
| YoY Change | ||
| Other Assets | $1.174B | $1.233B |
| YoY Change | 12.56% | 26.07% |
| Total Long-Term Assets | $36.37B | $37.64B |
| YoY Change | -13.83% | -14.48% |
| TOTAL ASSETS | ||
| Total Short-Term Assets | $12.82B | $13.01B |
| Total Long-Term Assets | $36.37B | $37.64B |
| Total Assets | $49.20B | $50.64B |
| YoY Change | -10.54% | -11.88% |
| SHORT-TERM LIABILITIES | ||
| YoY Change | ||
| Accounts Payable | $1.551B | $1.756B |
| YoY Change | -3.42% | 2.21% |
| Accrued Expenses | $2.318B | $2.581B |
| YoY Change | 0.83% | -3.69% |
| Deferred Revenue | ||
| YoY Change | ||
| Short-Term Debt | $23.00M | $514.0M |
| YoY Change | -95.52% | 0.0% |
| Long-Term Debt Due | $3.507B | $2.674B |
| YoY Change | 208.71% | 46.04% |
| Total Short-Term Liabilities | $12.69B | $13.16B |
| YoY Change | 8.0% | -3.73% |
| LONG-TERM LIABILITIES | ||
| Long-Term Debt | $21.60B | $22.73B |
| YoY Change | -12.24% | -7.45% |
| Other Long-Term Liabilities | $2.659B | $2.720B |
| YoY Change | -5.88% | -11.54% |
| Total Long-Term Liabilities | $24.26B | $25.45B |
| YoY Change | -11.59% | -7.91% |
| TOTAL LIABILITIES | ||
| Total Short-Term Liabilities | $12.69B | $13.16B |
| Total Long-Term Liabilities | $24.26B | $25.45B |
| Total Liabilities | $38.87B | $40.61B |
| YoY Change | -5.51% | -6.63% |
| SHAREHOLDERS EQUITY | ||
| Retained Earnings | ||
| YoY Change | ||
| Common Stock | ||
| YoY Change | ||
| Preferred Stock | ||
| YoY Change | ||
| Treasury Stock (at cost) | ||
| YoY Change | ||
| Treasury Stock Shares | ||
| Shareholders Equity | $10.32B | $10.03B |
| YoY Change | ||
| Total Liabilities & Shareholders Equity | $49.20B | $50.64B |
| YoY Change | -10.54% | -11.88% |
Cashflow Statement
| Concept | 2021 Q2 | 2020 Q4 |
|---|---|---|
| OPERATING ACTIVITIES | ||
| Net Income | $207.0M | $149.0M |
| YoY Change | 47.86% | 35.45% |
| Depreciation, Depletion And Amortization | $305.0M | $395.0M |
| YoY Change | -20.16% | -5.05% |
| Cash From Operating Activities | $218.0M | $331.0M |
| YoY Change | -20.15% | -38.48% |
| INVESTING ACTIVITIES | ||
| Capital Expenditures | -$113.0M | -$176.0M |
| YoY Change | -13.74% | 47.9% |
| Acquisitions | ||
| YoY Change | ||
| Other Investing Activities | $594.0M | $317.0M |
| YoY Change | 33.78% | -42.26% |
| Cash From Investing Activities | $481.0M | $141.0M |
| YoY Change | 53.67% | -67.21% |
| FINANCING ACTIVITIES | ||
| Cash Dividend Paid | ||
| YoY Change | ||
| Common Stock Issuance & Retirement, Net | ||
| YoY Change | ||
| Debt Paid & Issued, Net | ||
| YoY Change | ||
| Cash From Financing Activities | -1.000M | -125.0M |
| YoY Change | -66.67% | -48.13% |
| NET CHANGE | ||
| Cash From Operating Activities | 218.0M | 331.0M |
| Cash From Investing Activities | 481.0M | 141.0M |
| Cash From Financing Activities | -1.000M | -125.0M |
| Net Change In Cash | 698.0M | 347.0M |
| YoY Change | 19.73% | -52.27% |
| FREE CASH FLOW | ||
| Cash From Operating Activities | $218.0M | $331.0M |
| Capital Expenditures | -$113.0M | -$176.0M |
| Free Cash Flow | $331.0M | $507.0M |
| YoY Change | -18.07% | -22.83% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2020Q4 | us-gaap |
Debt Instrument Fair Value
DebtInstrumentFairValue
|
25891000000 | |
| dei |
Entity Registrant Name
EntityRegistrantName
|
TEVA PHARMACEUTICAL INDUSTRIES LTD | ||
| dei |
Entity Tax Identification Number
EntityTaxIdentificationNumber
|
00-0000000 | ||
| dei |
Entity Address Country
EntityAddressCountry
|
IL | ||
| CY2021Q2 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
||
| CY2021Q2 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
||
| CY2020Q2 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
||
| us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
|||
| us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
|||
| CY2020Q4 | us-gaap |
Goodwill
Goodwill
|
20624000000 | |
| CY2021Q2 | us-gaap |
Goodwill
Goodwill
|
20421000000 | |
| CY2021Q2 | us-gaap |
Long Term Debt Current
LongTermDebtCurrent
|
3507000000 | |
| CY2020Q4 | us-gaap |
Long Term Debt Current
LongTermDebtCurrent
|
2674000000 | |
| CY2021Q2 | us-gaap |
Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
|
32000000 | |
| CY2020Q2 | us-gaap |
Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
|
277000000 | |
| us-gaap |
Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
|
80000000 | ||
| us-gaap |
Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
|
352000000 | ||
| teva |
Utilization And Other
UtilizationAndOther
|
64000000 | ||
| teva |
Utilization And Other
UtilizationAndOther
|
150000000 |
